Balyasny Asset Management
ANAB icon

Balyasny Asset Management’s AnaptysBio ANAB Stock Holding History

Balyasny Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,000
Closed -$1.8M – 1369
2018
Q3 		$1.8M Buy
+20,000
New +$1.66M 0.01% 1016

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management's ANAB Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in AnaptysBio (ANAB) in Q1 2026: 4,905 shares worth $272K. The stake represents ﹤0.01% of the portfolio and ranks #2599 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ANAB as recently as Q2 2025.

Balyasny Asset Management first reported a position in ANAB in Q1 2018 and has held it in 8 quarters since. The position peaked at $15.7M in Q1 2018. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Balyasny Asset Management held 4,905 shares of AnaptysBio worth $272K as of Q1 2026.
  • AnaptysBio was a new Balyasny Asset Management position in Q1 2026.
  • AnaptysBio made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2599 holding.
  • Balyasny Asset Management first reported a position in AnaptysBio in Q1 2018 and has held it in 8 quarters since.
  • Balyasny Asset Management's AnaptysBio position peaked at $15.7M in Q1 2018.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.